|
Variable
|
Expenditure per patient during 2002–2011 (CNY)
|
Statisticsa
|
P
|
Expenditure per patient during 2009–2011 (CNY)
|
Statisticsa
|
P
|
|---|
|
Overall
|
38,666 (38,178–39,155)
| | |
45,319 (44,425–46,213)
| | |
|
Region
| |
649.44
|
<0.001
| |
306.1
|
<0.001
|
|
Eastern
|
41,943 (41,202–42,684)
| | |
47,213 (46,021–48,406)
| | |
|
Central
|
40,410 (39,646–41,173)
| | |
52,765 (51,100–54,430)
| | |
|
Western
|
30,234 (29,200–31,269)
| | |
32,555 (30,585–34,526)
| | |
|
Hospital type
|
−6.75
|
<0.001
| |
−1.20
|
0.228
|
|
General hospital
|
36,684 (35,663–37,704)
| | |
45,706 (43,883–47,529)
| | |
|
Specialized hospital
|
39,256 (38,700–39,812)
| | |
45,182 (44,157–46,207)
| | |
|
Hospital level
|
25.60
|
<0.001
| |
13.26
|
<0.001
|
|
3A
|
40,134 (39,625–40,643)
| | |
46,751 (45,824–47,677)
| | |
|
3A less
|
22,052 (20,621–23,483)
| | |
26,409 (23,612–29,206)
| | |
|
Number of clinical visits per patient
|
889.53
|
<0.001
| |
204.28
|
< 0.001
|
|
1
|
29,089 (28,651–29,528)
| | |
34,858 (33,981–35,735)
| | |
|
2
|
46,633 (45,530–47,737)
| | |
53,959 (52,002–55,917)
| | |
|
3
|
59,441 (57,524–61,357)
| | |
60,407 (57,497–63,317)
| | |
|
4+
|
68,928 (66,774–71,082)
| | |
69,055 (65,749–72,360)
| | |
|
Gender
|
5.64
|
<0.001
| |
1.84
|
0.066
|
|
Male
|
39,521 (38,961–40,082)
| | |
46,046 (45,017–47,074)
| | |
|
Female
|
35,585 (34,605–36,564)
| | |
42,768 (40,976–44,561)
| | |
|
Age at diagnosis (years)
|
8.65
|
<0.001
| |
14.42
|
<0.001
|
|
<45
|
37,796 (35,539–40,054)
| | |
49,384 (43,380–55,388)
| | |
|
45–54
|
39,237 (38,172–40,302)
| | |
50,732 (48,367–53,096)
| | |
|
55–64
|
39,588 (38,792–40,384)
| | |
46,572 (45,139–48,006)
| | |
|
≥65
|
37,452 (36,647–38,257)
| | |
41,741 (40,426–43,057)
| | |
|
Pathologic type
|
23.95
|
<0.001
| |
11.61
|
<0.001
|
|
Squamous cell carcinoma
|
40,711 (40,173–41,250)
| | |
48,242 (47,233–49,250)
| | |
|
Others
|
30,216 (29,032–31,399)
| | |
35,576 (33,636–37,516)
| | |
|
Clinical stage
|
55.51
|
<0.001
| |
21.80
|
<0.001
|
|
I
|
34,460 (32,902–36,017)
| | |
40,000 (36,878–43,122)
| | |
|
II
|
39,302 (38,526–40,079)
| | |
47,978 (46,381–49,575)
| | |
|
III
|
40,353 (39,491–41,214)
| | |
44,962 (43,616–46,309)
| | |
|
IV
|
37,432 (36,180–38,685)
| | |
42,972 (40,749–45,194)
| | |
|
Type of therapy
| |
758.66
|
<0.001
| |
270.53
|
<0.001
|
|
Surgery
|
38,492 (37,890–39,094)
| | |
47,778 (46,548–49,008)
| | |
|
Surgery and chemotherapy
|
51,503 (50,316–52,691)
| | |
63,843 (61,535–66,151)
| | |
|
Radiotherapy
|
27,933 (26,787–29,079)
| | |
29,085 (27,471–30,699)
| | |
|
Chemotherapy
|
27,805 (26,310–29,299)
| | |
35,671 (33,121–38,222)
| | |
|
Radiotherapy and chemotherapy
|
53,907 (51,867–55,946)
| | |
57,234 (53,865–60,603)
| | |
|
Surgery and radiotherapy
|
57,725 (55,041–60,409)
| | |
62,438 (58,708–66,167)
| | |
|
Palliative care
|
13,846 (12,626–15,067)
| | |
15,627 (13,187–18,067)
| | |
|
Others
|
23,057 (20,564–25,550)
| | |
21,821 (18,386–25,256)
| | |
- All expenditure data are presented as mean with 95% confidence interval in parentheses
-
CNY Chinese Yuan
-
aThe two-sample Student t test after logarithm transition was used for binary classification variables, including hospital type, hospital level, gender, and pathologic type. The ANOVA test after logarithm transition was used for other multiple categorical variables, including region, number of clinical visits per patient, age at diagnosis, and clinical stage
